Selank has an unusually tangled status: a prescription anxiety medication in one country, a "research chemical" in another, and a moving regulatory target in 2026. Here's where it actually stands in the US.
Not FDA-approved here
In the United States, Selank is not FDA-approved for any use. It has been used and studied for anxiety in Russia, where most of its research originates, but that approval doesn't carry over to the US.
The 2026 reclassification
Selank was among the peptides caught in the FDA's 2023 restriction. In 2026 the agency began reassessing that group, removing a set of peptides from the restricted Category 2 list and sending seven specific peptides to an advisory committee that met in July 2026. That panel recommended six of the seven (Semax among them) for the compoundable list, but Selank was not on the agenda at all — so its formal status simply remains unsettled, and even the recommended peptides still await FDA rulemaking. We post changes as they happen on 2026 Updates.
Why "research use only" isn't a loophole
Most Selank sold online carries a "not for human consumption" label. That label doesn't make human use legal or safe, it's the same pattern the FDA has cited in warning letters across the peptide space.
Bottom line
Selank is not FDA-approved in the US, its compounding status is unsettled and changing in 2026, and online "research" versions are a gray zone. A licensed provider is the right person to explain the current rules.